Aspirin overutilization for the primary prevention of cardiovascular disease

Clinical Epidemiology

Volumn 6, Issue , 2014, Pages 433-440

  VanWormer, Jeffrey J ^a   Miller, Aaron W ^a   Rezkalla, Shereif H ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Adults; Aspirin; Cardiovascular disease; Primary prevention; United States

Indexed keywords

EID: 84914099894     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S72032     Document Type: Article

References (46)

1. Hsu S, Ton VK, Dominique Ashen M, et al. A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource approach to the Million Hearts Initiative. Clin Cardiol. 2013;36:383-393.
2. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6:95-107.
3. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002;136:157-160.
4. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52-61.
5. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796-1801.
6. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among US adults: behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74-77.
7. Sanchez DR, Diez Roux AV, Michos ED, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol. 2011;107:41-46.
8. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403-407.
9. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ. 2010;340:c1805.
10. Sanchez-Ross M, Waller AH, Maher J, et al. Aspirin for the prevention of cardiovascular morbidity. Minerva Med. 2010;101:205-214.
11. Filippi A, Bianchi C, Parazzini F, et al. A national survey on aspirin patterns of use and persistence in community outpatients in Italy. Eur J Cardiovasc Prev Rehabil. 2011;18:695-703.
12. Rodondi N, Cornuz J, Marques-Vidal P, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med. 2008;46:137-144.
13. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-2294.
14. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med. 2009;150:396-404.
15. US Food and Drug Administration. Use of Aspirin for Primary Prevention of Heart Attack and Stroke [updated June 13, 2014]. Available from: http://www.fda.gov/drugs/resourcesforyou/consumers/ucm390574.htm. Accessed June 27, 2014.
16. Manes C, Giacci L, Sciartilli A, D'Alleva A, De Caterina R. Aspirin overprescription in primary cardiovascular prevention. Thromb Res. 2006;118:471-477.
17. Kale MS, Bishop TF, Federman AD, Keyhani S. Trends in the overuse of ambulatory health care services in the United States. JAMA Intern Med. 2013;173:142-148.
18. VanWormer JJ, Greenlee RT, McBride PE, et al. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract. 2012;61: 525-532.
19. DeStefano F, Eaker ED, Broste SK, et al. Epidemiologic research in an integrated regional medical care system: the Marshfield Epidemiologic Study Area. J Clin Epidemiol. 1996;4:643-652.
20. Greenlee RT. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res. 2003;1:273-280.
21. VanWormer JJ, Miller AW, Rezkalla SH. Identifying opportunities to improve aspirin utilization for the primary prevention of cardiovascular disease in a regional healthcare system. WMJ. 2014;113(5):190-195.
22. American Society of Health-System Pharmacists. AHFS Drug Information 2013. Bethesda, MD: American Society of Health-System Pharmacists; 2013.
23. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
24. Cody RP, Smith JK. Applied Statistics and the SAS Programming Language. New York, NY: Prentice Hall; 2005.
25. Kastorini CM, Georgousopoulou E, Vemmos KN, et al. Comparative analysis of cardiovascular disease risk factors influencing nonfatal acute coronary syndrome and ischemic stroke. Am J Cardiol. 2013;112: 349-354.
26. Prasad C, Batsis JA, Lopez-Jimenez F, Clark MM, et al. Risk perception of obesity and bariatric surgery in patients seeking treatment for obesity. Eur J Prev Cardiol. 2012;21:692-703.
27. Hernandez-Boussard T, Ahmed SM, Morton JM. Obesity disparities in preventive care: findings from the National Ambulatory Medical Care Survey, 2005-2007. Obesity. 2012;20:1639-1644.
28. Bertakis KD, Azari R. The impact of obesity on primary care visits. Obes Res. 2005;13:1615-1623.
29. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499-510.
30. Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of US physicians. BMC Health Serv Res. 2012;12:20.
31. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
32. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation. 2009;119:3078-3084.
33. Freiberg MS, Pencina MJ, D'Agostino RB, et al. BMI vs waist circumference for identifying vascular risk. Obesity. 2008;16:463-469.
34. Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions. Am J Med. 2013;126:373-378.
35. Morgan G, Elwood P. Aspirin bleeding in perspective. Qual Prim Care. 2011;19:251-253.
36. Adly G, Plakogiannis R. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature. Ann Pharmacother. 2013;47:e8.
37. Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G. Platelet activation in obesity and metabolic syndrome. Obes Rev. 2012;13:27-42.
38. O'Connor PJ, Pronk NP, Tan AW, Rush WA, Gray RJ. Does professional advice influence aspirin use to prevent heart disease in an HMO population? Eff Clin Pract. 1998;1:26-32.
39. Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention. Can Fam Physician. 2013;59:55-61.
40. Sheridan SL, Draeger LB, Pignone MP, et al. A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies. BMC Health Serv Res. 2011;11:331.
41. Appana D, Sperl-Hillen J, Ekstrom H, et al. Aspirin decision support using data-driven treatment algorithms. Clin Med Res. 2013;11: 136-137.
42. Benson GA, Sidebottom A, VanWormer JJ, et al. HeartBeat Connections: a rural community of solution for cardiovascular health. J Am Board Fam Med. 2013;26:299-310.
43. Folks B, Leblanc WG, Staton EW, Pace WD. Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. Implement Sci. 2011;6:65.
44. Wisconsin Collaborative for Healthcare Quality. Ischemic Vascular Disease: Daily Aspirin or Other Antiplatelet Therapy. Available from: http://www.wchq.org/reporting/results.php?category_id=0&topic_id=27&source_id=0&providerType=0®ion=0&measure_id=156. Accessed July 7, 2014.
45. Zantek ND, Luepker RV, Duval S, et al. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. Clin Appl Thromb Hemost. 2014;20:385-392.
46. Pakhomov SV, Shah ND, Hanson P, Balasubramaniam SC, Smith SA. Automated processing of electronic medical records is a reliable method of determining aspirin use in populations at risk for cardiovascular events. Inform Prim Care. 2010;18:125-133.